CDTX — Cidara Therapeutics Share Price
0.000.00%
Last trade - 00:00- $1.65bn
- $1.14bn
- $1.28m
- 39
- 29
- 100
- 57
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.3 | ||
| Price to Tang. Book | 3.3 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -24.75% | ||
| Return on Equity | -37.05% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 12.07 | 49.57 | 64.45 | 23.28 | 1.27 | n/a | 4.5 | -42.85% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cidara Therapeutics, Inc. is a biotechnology company. The Company is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The Company is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.
Directors
- Daniel Burgess NEC (59)
- Jeffrey Stein PRE (66)
- Preetam Shah CFO (49)
- Paul Daruwala COO (52)
- Brady Johnson CAO
- Jessica Oien GCN (50)
- Taylor Sandison OTH (49)
- Bonnie Bassler IND (59)
- Carin Canale - Theakston IND (47)
- Timothy Franson IND (69)
- David Gollaher IND (71)
- Chrysa Mineo IND (56)
- Theodore Schroeder IND (66)
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- December 6th, 2012
- Public Since
- April 15th, 2015
- No. of Employees
- 69
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 25,358,051
- Address
- 6310 Nancy Ridge Dr Ste 101, SAN DIEGO, 92121-3209
- Web
- https://www.cidara.com/
- Phone
- +1 8587526170
- Contact
- Brian Ritchie
- Auditors
- Ernst & Young LLP
Upcoming Events for CDTX
Similar to CDTX
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
What is the Cidara Therapeutics share price?
As of Today at 19:57 UTC, shares in Cidara Therapeutics are trading at $65.22. This share price information is delayed by 15 minutes.
How has the Cidara Therapeutics share price performed this year?
Shares in Cidara Therapeutics last closed at $65.22 and the price had moved by +415.94% over the past 365 days. In terms of relative price strength the Cidara Therapeutics share price has outperformed the S&P500 Index by +344.3% over the past year.
What are the analyst and broker recommendations for Cidara Therapeutics?
The overall consensus recommendation for Cidara Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Cidara Therapeutics dividend yield?
Cidara Therapeutics does not currently pay a dividend.
Does Cidara Therapeutics pay a dividend?
Cidara Therapeutics does not currently pay a dividend.
When does Cidara Therapeutics next pay dividends?
Cidara Therapeutics does not currently pay a dividend.
How do I buy Cidara Therapeutics shares?
To buy shares in Cidara Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cidara Therapeutics?
As of the previous close price of $65.22, shares in Cidara Therapeutics had a market capitalisation of $1.65bn.
Where are Cidara Therapeutics shares listed?
Here are the trading details for Cidara Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CDTX
What kind of share is Cidara Therapeutics?
Based on an overall assessment of its quality, value and momentum Cidara Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cidara Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Cidara Therapeutics is $83.43. That is 27.93% above the last closing price of $65.22.
Analysts covering Cidara Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$6.74 for the next financial year.
Find out moreWhat is the trend in the Cidara Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cidara Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +158.89%.
As of the last closing price of $65.22, shares in Cidara Therapeutics were trading +134.02% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cidara Therapeutics PE Ratio?
The Cidara Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $65.22.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cidara Therapeutics?
Cidara Therapeutics' management team is headed by:
- Daniel Burgess - NEC
- Jeffrey Stein - PRE
- Preetam Shah - CFO
- Paul Daruwala - COO
- Brady Johnson - CAO
- Jessica Oien - GCN
- Taylor Sandison - OTH
- Bonnie Bassler - IND
- Carin Canale - Theakston - IND
- Timothy Franson - IND
- David Gollaher - IND
- Chrysa Mineo - IND
- Theodore Schroeder - IND